The U.S. prohibits gene therapies that alter sperm or eggs, preventing hereditary changes. China's more permissive stance on this "germline editing" allows its researchers to pursue permanent cures for genetic diseases, giving them a significant lead in a revolutionary field.

Many object to embryo selection because they mistakenly believe it involves altering genes. In reality, the technology simply reveals information about natural genetic variations already present in IVF embryos, allowing parents to choose, not tinker.

Dr. Marson draws a clear ethical line between somatic edits (in an individual's non-reproductive cells) and germline edits (in sperm, eggs, or embryos). He believes we should not introduce heritable genetic changes, citing concerns about losing human diversity through genetic "fads" and unforeseen consequences.

Up to 40% of natural conceptions are spontaneously aborted, often before a woman knows she's pregnant. This is typically the body's way of rejecting embryos with severe genetic abnormalities. This natural process provides a powerful biological precedent for the practice of pre-implantation genetic screening.

To normalize the ethically fraught practice of embryo gene editing, startups like Preventive are shifting the narrative from just curing disease to radical cost reduction. They claim editing embryos could cost $5,000, a fraction of the $2 million price tag for current adult gene therapies.

A new innovation allows companies to construct an embryo's entire genome using raw data from a standard Down syndrome test. This means parents can get comprehensive polygenic reports without needing explicit approval from clinics or doctors, effectively democratizing access and removing traditional medical gatekeepers.

Standard IVF practice involves a doctor visually selecting the embryo that appears most "normally shaped." This is already a form of selection. Polygenic screening simply replaces this subjective "eyeballing" method with quantitative genetic data for a more informed choice, making it an evolution, not a revolution.

As a co-founder of a longevity biotech firm, Brian Armstrong predicts a 50% chance of reaching "longevity escape velocity" by 2030-2035. This is the point where medicine adds more than a year to life expectancy for every year that passes, driven by breakthroughs in AI-powered drug discovery and cellular analysis.

Polygenic embryo screening, while controversial, presents a clear economic value proposition. A $3,500 test from Genomic Prediction that lowers Type 2 Diabetes risk by 12% implies that avoiding the disease is worth over $27,000. This reframes the service from 'designer babies' to a rational financial decision for parents.